Deciphera Pharmaceuticals Inc (DCPH)
25.54
+0.01
(+0.04%)
USD |
NASDAQ |
May 31, 16:00
25.54
0.00 (0.00%)
After-Hours: 20:00
Deciphera Pharmaceuticals Research and Development Expense (Annual): 234.12M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 234.12M |
| December 31, 2022 | 187.82M |
| December 31, 2021 | 257.04M |
| December 31, 2020 | 198.97M |
| December 31, 2019 | 157.61M |
| Date | Value |
|---|---|
| December 31, 2018 | 82.89M |
| December 31, 2017 | 39.51M |
| December 31, 2016 | 20.16M |
| December 31, 2015 | 12.48M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
157.61M
Minimum
2019
257.04M
Maximum
2021
207.11M
Average
198.97M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Bristol-Myers Squibb Co | 9.299B |
| Dynavax Technologies Corp | 54.89M |
| Gilead Sciences Inc | 5.718B |
| Esperion Therapeutics Inc | 86.11M |
| SINTX Technologies Inc | 8.713M |